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Background: A number of oral diseases, including periodontitis, derive from microbial biofilms and are associated
with increased antimicrobial resistance. Despite the widespread use of mouthwashes being used as adjunctive
measures to control these biofilms, their prolonged use is not recommended due to various side effects. Therefore,
alternative broad-spectrum antimicrobials that minimise these effects are highly sought after. Carbohydrate derived
fulvic acid (CHD-FA) is an organic acid which has previously demonstrated to be microbiocidal against Candida
albicans biofilms, therefore, the aims of this study were to evaluate the antibacterial activity of CHD-FA against
orally derived biofilms and to investigate adjunctive biological effects.
Methods: Minimum inhibitory concentrations were evaluated for CHD-FA and chlorhexidine (CHX) against a range
of oral bacteria using standardised microdilution testing for planktonic and sessile. Scanning electron microscopy
was also employed to visualise changes in oral biofilms after antimicrobial treatment. Cytotoxicity of these
compounds was assessed against oral epithelial cells, and the effect of CHD-FA on host inflammatory markers was
assessed by measuring mRNA and protein expression.
Results: CHD-FA was highly active against all of the oral bacteria tested, including Porphyromonas gingivalis, with a
sessile minimum inhibitory concentration of 0.5%. This concentration was shown to kill multi-species biofilms by
approximately 90%, levels comparable to that of chlorhexidine (CHX). In a mammalian cell culture model,
pretreatment of epithelial cells with buffered CHD-FA was shown to significantly down-regulate key inflammatory
mediators, including interleukin-8 (IL-8), after stimulation with a multi-species biofilm.
Conclusions: Overall, CHD-FA was shown to possess broad-spectrum antibacterial activity, with a supplementary
function of being able to down-regulate inflammation. These properties offer an attractive spectrum of function
from a naturally derived compound, which could be used as an alternative topical treatment strategy for oral
biofilm diseases. Further studies in vitro and in vivo are required to determine the precise mechanism by which
CHD-FA modulates the host immune response.
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Dental caries, gingivitis and periodontitis are the most
common microbial diseases of the oral cavity, with the
majority associated with a polymicrobial biofilm [1,2].
Biofilms are a collection of multicellular microorganisms
attached to one another or upon a surface, and are
embedded by a protective layer of extracellular matrix
(ECM) [3]. Biofilms are of greater clinical importance
than their free-floating planktonic counterparts because
of their innate ability to resist antimicrobial therapy and
host defences. This is due to the extensive ECM produc-
tion and other factors such as increased extrusion of an-
timicrobials through enhanced efflux pump activity [3,4].
Antimicrobial mouthwashes are one of the main thera-
peutic and preventative strategies currently used in the
management of oral biofilm diseases, of which chlor-
hexidine (CHX) is widely accepted as the ‘gold standard’
[5]. This antiseptic agent has superior activity to its
comparators, and is both cidal and static against micro-
organisms present in oral biofilms with roles in the
pathogenesis of oral disease. Moreover, its substantivity
provides prolonged activity through its ability to adsorb
onto the pellicle found on enamel surfaces of teeth [6].
Despite this, various studies have shown long-term use
of CHX may not be practical as it is associated with
staining of the teeth and taste alterations [7,8]. Fur-
thermore, recent reports of adverse events, including
anaphylactic reactions, to this compound have been de-
scribed [9]. It has also been shown recently to be inef-
fective against biofilms grown from clinical isolates [10].
The prevention and treatment of oral biofilm diseases,
such as periodontal diseases and mucosal infections,
may benefit from a compound that has the potency of
CHX with minimal side effects, but also elicits adjunct-
ive biological properties, such as alteration of infla-
mmatory pathways, which are clearly important in the
pathogenesis of oral biofilm disease [11,12]. A previous
study has shown CHX is able to down-regulate inflamma-
tory mediators when challenged with a bacterial stimuli
[13], though toxicological aspects of CHX may be the rea-
son for the decreased expression. We have also shown the
benefit of using natural agents in the management of oral
infections, where tea tree oil (TTO) was not only non-
toxic, but was able to dampen the host immune response
to a fungal stimulus [14]. Furthermore, our group have
previously assessed the antiseptic activity of carbohydrate-
derived fulvic acid (CHD-FA), where it was shown that the
compound was equally effective against Candida albicans
planktonic and biofilm cells. Mechanistically this was
identified as a membrane disruption process that was not
impacted by defined biofilm adaptive resistance mecha-
nisms [15]. CHD-FA is a colloidal organic acid, which is a
major constituent of humic acids. A purified form of
CHD-FA has recently been produced by a patentedprocess, which has been shown to be non-toxic in a rat
wound model, with suggestions of anti-inflammatory ac-
tivity [16]. Moreover, a recent randomized, double blind,
controlled trial indicated that it was well-tolerated in a
clinical study of eczema [17].
The purpose of this study was to investigate whether
CHD-FA has a broad-spectrum of activity against micro-
bial biofilms of oral relevance to determine whether it
could be used as an alternative to CHX based mouth-
washes, which have known side effects from prolonged
use. The secondary aim of the study was to determine
whether the antibacterial concentration of CHD-FA had
any adjunctive immunomodulatory properties, as reported
elsewhere [16]. We report that CHD-FA displays rapid
microbiocidal activity against orally relevant biofilms, and
that it is also able to down-regulate the expression of pro-
inflammatory molecules in orally relevant epithelial cells.Methods
Culture conditions and standardisation
A selection of laboratory strains of commensal and patho-
genic bacteria associated with oral biofilms disease were
used in this study, including Porphyromonas gingivalis
ATCC 33277 and Fusobacterium nucleatum ATCC 10596,
which were maintained at 37°C on fastidious anaerobic
agar (FAA [Lab M, Lancashire, UK]) under anaerobic con-
ditions (85% N2, 10% CO2 and 5% H2, [Don Whitley
Scientific Limited, Shipley, UK]). Streptococcus mutans
10449, Streptococcus mitis NCTC 12261, Aggregatibacter
actinomycetemcomitans OSM 1123 and Enterococcus
faecalis NCTC 5957 were grown and maintained at 37°C
on Colombia blood agar (CBA [Oxoid, Hampshire, UK] in
5% CO2. All isolates were stored indefinitely in Microbank®
vials (Pro-Lab Diagnostics, Cheshire, UK) at −80°C.
P. gingivalis and F. nucleatum were propagated in 10 ml
Schaedler’s anaerobic broth (Oxoid), S. mitis and
A. actinomycetemcomitans were grown in 10 ml Tryptic
Soy Broth (TSB [Sigma-Aldrich, Dorset, UK]) supplemented
with 0.6% yeast extract and 0.8% glucose. E. faecalis was
grown in TSB with 0.25% glucose, and S. mutans was grown
in 10 ml brain heart infusion (BHI [Sigma-Aldrich]), all at
37°C and at appropriate atmospheric conditions. Over-
night cultures were washed by centrifugation (1000 xg)
and resuspended in 10 ml PBS. All bacteria were then
standardised and adjusted to a final working concentration
of 5 × 104 and 1 × 107 cells/ml for planktonic and sessile
susceptibility testing, respectively.Antibacterial susceptibility testing of planktonic and
biofilm cells
During the course of this study two active compounds
from the oral hygiene products Dentracine (Fulhold Ltd,
Cape Town, South Africa) and Corsodyl (GlaxoSmithKline
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and CHX, respectively.
Antimicrobial testing to determine minimum inhibi-
tory concentrations (MICs) of planktonic cells (PMIC)
was performed using the CLSI M11-A8 broth micro-
dilution method for anaerobic bacteria [18] and CLSI
M7-A9 for bacteria grown in 5% CO2 [19]. Minimum
bactericidal concentrations (MBC) were also determined
by standard plating methods.
For biofilm testing standardised P. gingivalis, F.
nucleatum, S. mitis and A. actinomycetemcomitans
were grown for 72 h and E. faecalis for 24 h in their
respective media and atmospheric conditions, with the
exception of S. mutans which was grown in BHI
supplemented with 2% sucrose for 48 h. Biofilms were
grown statically in commercially available 96-well flat
bottomed microtitre plates (Corning Incorporated, NY,
USA) and sessile susceptibility testing was performed as
described elsewhere [20]. Following antimicrobial treat-
ment, biofilms were washed twice with PBS and 10%
alamarBlue® (Invitrogen, Paisley, UK) was added to the
biofilms prior to incubation for 4 h in the dark [21]. Ses-
sile minimum inhibitory concentrations (SMICs) were
read visually and no change in colour was defined as the
SMIC. Testing of all planktonic and sessile isolates was
performed in quadruplicate on two separate occasions.
Antibacterial susceptibility testing of a multi-species
periodontal biofilm
A multi-species periodontal biofilm model consist-
ing of P. gingivalis, F. nucleatum, S. mitis and A.
actinomycetemcomitans was developed for antimicro-
bial testing. All bacterial species were standardised to
1 × 107 cfu/mL in artificial saliva (AS) as previously de-
scribed [22]. This was comprised of porcine stomach
mucins (0.25% w/v), sodium chloride (0.35 w/v), potas-
sium chloride (0.02 w/v), calcium chloride dihydrate
(0.02 w/v), yeast extract (0.2 w/v), lab lemco powder
(0.1 w/v), proteose peptone (0.5 w/v) in ddH2O. Urea
was diluted in PBS (40% w/v) and added to a final concen-
tration of 0.05% (v/v) in AS. Biofilms were prepared in 24
well plates (Corning, NY, USA) containing customised
Thermanox™ coverslips (13 mm diameter, Fisher Scien-
tific). For the addition of each bacterial species to the bio-
film a standardised bacterial suspension was prepared in
500 μL of AS. Initially, S. mitis biofilms were grown
for 24 h. Media was then removed and standardised
F. nucleatum added, which was incubated anaerobically for
a further 24 h. The supernatant was again removed and
standardised P. gingivalis and A. actinomycetemcomitans in
AS added to the biofilm. This was then incubated at 37°C
in an anaerobic chamber for a further 4 days; each day su-
pernatants were replaced with fresh AS. As CHD-FA was
shown to be active at 0.5% v/v against all bacterial biofilmstested in this study, this concentration was used in addition
to 0.2% v/v CHX to treat multispecies biofilms for 30 min,
before carefully washed with PBS, and biofilm viability de-
termined using alamarBlue®. The absorbance was read at
570 nm and the reference wavelength at 600 nm. The per-
centage reduction in biofilm viability was calculated
according to the manufacturer’s instructions. This study
was performed on three separate occasions in triplicate.
Following the antimicrobial treatment, biofilms were
retained and used to quantify the number of each bacte-
rial species found after CHD-FA and CHX treatment
compared to the untreated control. Briefly, biofilms were
sonicated in 1 mL of PBS for 10 min and DNA extracted
using the MasterPure Gram Positive DNA Purificiation
Kit (Epicentre®, Cambridge, UK), following manufacturers
instructions. 1 μL of extracted DNA was added to a
mastermix containing 12.5 μL SYBR® GreenER™, 9.5 μL
UV-treated RNase-free water and 1 μL of 10 μM forward/
reverse primers for each bacterial species. The primers
used were as follows:
A. actinomycetemcomitans F – 5′GAACCTTACCT
ACTCTTGACATCCGAA3′, A. actinomycetemcomitans
R – 5′TGCAGCACCTGTCTCAAAGC3′, F. nucleatum
F – 5′GGATTTATTGGGCGTAAAGC3′, F. nucleatum
R – 5′GGCATTCCTACAAATATCTACGAA3′, P. gingi-
valis F – 5′GCGCTCAACGTTCAGCC3′, P. gingivalis
R – 5′CACGAATTCGCCTGC3′, S. mitis F – 5′GATA
CATAGCCGACCTGAG3′, S. mitis R – 5′CCATTGCC
GAAGATTCC3′.
Three independent replicates from each parameter
were analysed in triplicate using MxProP Quantitative
PCR machine and MxProP 3000 software (Stratagene,
Amsterdam, Netherlands). Samples were quantified
based upon a previously established standard curve
made up of known bacterial counts.Ultrastructural changes of bacterial biofilms
Scanning electron microscopy (SEM) was performed
on S. mutans, E. faecalis, and the multispecies biofilms.
Cells were standardised in appropriate media, as de-
scribed above, and grown directly onto Thermanox™
coverslips (Nunc, Roskilde, Denmark) to allow biofilm
formation. Following maturation biofilms were care-
fully washed with PBS before their respective treat-
ments. Biofilms were then carefully washed twice with
PBS and then fixed in 2% para-formaldehyde, 2%
gluteraldehyde and 0.15 M sodium cacodylate, and
0.15% w/v Alcian Blue, pH 7.4, and prepared for SEM
as previously described [23]. The specimens were
sputter-coated with gold and viewed under a JEOL
JSM-6400 scanning electron microscope. Images were
assembled using Photoshop software (Adobe, San Jose,
CA, USA).
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OKF6/TERT2 cells (gifted by the Rheinwald laboratory,
Brigham and Woman’s Hospital, Boston, USA), an immor-
talised human oral keratinocyte cell line, were used for
determining the cytotoxicity of CHD-FA. Cells were
grown to 90% confluence in keratinocyte serum-free
medium (KSFM) at 37°C in 5% CO2 and seeded at a dens-
ity of 1 × 105 cells/ml in a 24 well plate. Once the cells
reached 80-90% confluence, the cells were carefully
washed with PBS before treatment with 0.5% (v/v) CHD-
FA at the native pH 2.0 and a neutral pH of 7.0 and 0.2%
(v/v) CHX for 30 min. After 30 min, the compounds were
removed and the cells carefully washed with PBS to re-
move any residual actives. Cells were incubated in KSFM
for 4 and 24 h before cellular viability was assessed using
the alamarBlue® assay, as described above. Viability studies
were carried out in triplicate, on three separate occasions.
Assessing immunomodulatory properties of CHD-FA
OKF6/TERT2 cells were grown to 90% confluence in 24
well plates in defined-KSFM then pre-treated with 0.5%
CHD-FA (pH 7.0) for 30 min. CHD-FA at pH 2.0 was
toxic against the cell line used in this study and therefore
could not allow us to analyse any potential immunomodu-
latory properties of this compound. Therefore, CHD-FA
buffered to pH 7.0 was used to assess any further bio-
logical properties of the compound. 0.5% CHD-FA at
pH 2.0 and 0.2% CHX were shown to be toxic to epithelial
cells, so were not further investigated. Cells were washed
with PBS to remove residual CHD-FA. As an inflamma-
tory agonist we used the multispecies periodontal biofilm,
as described above, which was attached to the underside
of a hanging cell culture insert (Millipore, Massachusetts,
USA) using Vaseline®, then laid adjacent to the cell mo-
nolayer. The cells were incubated with the periodontal
biofilm for 4 and 24 h at 37°C in 5% CO2. Cells not pre-
treated with CHD-FA, or not challenged with biofilms,
served as appropriate controls. Following stimulation, su-
pernatants and cell lysates were retained to assess the
regulation of a panel of pro-inflammatory mediators.
Initial gene expression analysis was carried out using a
custom designed RT2 Profiler PCR Array (Qiagen,
Crawley, UK). RT2 Profiler arrays are a SYBR® GreenER™
based real-time PCR that allow for the detection of sev-
eral genes of interest, simultaneously. Briefly, 24 μl of a
mastermix containing SYBR® GreenER™, cDNA synthe-
sised using the RT2 First Strand kit (Qiagen) and RNase-
free water was added to each well of the RT2 Profiler
plate, which already contained the forward and reverse
primers for the genes of interest (IL-1α, IL-1β, IL-6,
TNF, CSF2, CSF3, IL-8, CXCL1, CXCL3, CXCL5, CCL1
and GAPDH). Two replicates of each condition were
used in the RT2 Profiler, which was carried out on two
separate occasions.IL-8 gene expression was analysed using SYBR® Green
based qPCR (Invitrogen), using GAPDH as a housekeep-
ing gene. The primers used were as follows: IL-8 F 5′
CAGAGACAGCAGAGCACACAA3′, IL-8 R 5′TTAGC
ACTCCTTGGCAAAAC3′, GAPDH F 5′CAAGGCTGA
GAACGGGAAG3′, GAPDH R 5′GGTGGTGAAGACG
CCAGT3′. Briefly, RNA was extracted from cell lysates
(Qiagen, Crawley, UK) and 55 ng/μl of cDNA synthe-
sised using the RT2 First Strand cDNA synthesis kit
(Qiagen, Crawley, UK), as per manufacturers instruc-
tions. 1 μl of synthesised cDNA was added to a master-
mix containing 12.5 μl SYBR® GreenER™, 10.5 μl UV-
treated RNase-free water and 0.5 μl of forward/reverse
primers. Three independent replicates from each param-
eter were analysed in duplicate using MxProP Quantitative
PCR machine and MxProP 3000 software (Stratagene,
Amsterdam, Netherlands) and gene expression normalised
to the housekeeping gene GAPDH according to the 2-ΔΔCT
method [24].
Interleukin 8 (IL-8) release into cell culture supernatants
was assessed by ELISA (Invitrogen, Paisley, UK), as per
manufacturer’s instructions. Results were calculated using
a 4-parameter curve fit, quantifying colometric changes at
630 nm (BMG-Labtech, Ortenberg, Germany).
Statistical analysis
Graph production, data distribution and statistical ana-
lysis were performed using GraphPad Prism (version 4;
La Jolla, CA, USA). After assessing whether data con-
formed to a normal distribution by before and after data
transforms, One-way Analysis of Variance (ANOVA) and
t tests were used to investigate significant differences be-
tween independent groups of data that approximated to a
Gaussian distribution. A Bonferroni correction was ap-
plied to the p value to account for multiple comparisons
of the data. Non-parametric data was analysed using the
Mann–Whitney U-test to assess differences between two
independent sample groups. Student t-tests were used to
measure statistical differences between the ΔCt values of
the two independent groups assessed in gene expression
studies, although data may be represented as percentage
or fold change in the figures. Statistical significance was
achieved if P < 0.05.
Results
CHD-FA has rapid and broad-spectrum antibacterial
activity
Corsodyl® (0.2% CHX) and Dentracine (0.8% CHD-FA)
are oral formulations containing the active ingredients
CHX and CHD-FA, respectively. Both agents were
shown to be highly active against all planktonic and ses-
sile oral bacteria tested (data not shown). The studies
described in this manuscript focussed on the active in-
gredients CHX and CHD-FA and both were shown to be
Table 1 Susceptibility profile of clinically relevant oral bacteria to four antimicrobial agents
MIC (%)
CHD-FA CHX
Organism PMIC MBC SMIC Fold change PMIC MBC SMIC Fold change
(SMIC/PMIC) (SMIC/PMIC)
A. a* 0.25 0.25 0.5 2 0.00078 0.00313 0.025 32
S. mitis 0.0625 0.125 0.5 8 0.00078 0.00156 0.0125 16
S. mutans 0.25 0.25 0.5 2 0.00039 0.00078 0.025 64
E. faecalis 0.125 0.25 0.5 4 0.00156 0.025 0.003 2
F. nucleatum 0.125 0.5 0.5 4 0.00039 0.00078 0.195 32
P. gingivalis 0.0625 0.5 0.5 8 ≤0.00039 0.00078 0.0625 ≥16
*A. actinomycetemcomitans.
CHD-FA - (Fulhold Ltd, South Africa), CHX - (GlaxoSmithKline Consumer Health Care, UK).
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tested when grown either planktonically and as biofilms
(Table 1). PMICs for the oral isolates ranged from
0.0625% to 0.25% for CHD-FA and from <0.00039% to
0.00078% for CHX. The PMBC/PMIC ratio for CHD-FA
and CHX were ≤4, indicating both compounds displayedFigure 1 CHD-FA reduces ECM and compromises cell membrane stru
untreated (A and C, respectively) or treated with 0.5% (v/v) CHD-FA (B and
processed and viewed on a JEOL JSM-6400 scanning electron microscope
in extracellular matrix (B) and perturbation of bacterial cell membranes (D)bactericidal activity. None of the bacterial species tested
were notably more sensitive or resistant to either of the
compounds. Both CHD-FA and CHX showed activity
against mature biofilms, with SMICs of 0.5% for CHD-FA
and from 0.003% to 0.025% for CHX. Interestingly, al-
though CHX was effective at lower concentrations, thecture. S. mutans (x2000) and E. faecalis (x5000) biofilms were either
D, respectively) for 24 h on Thermanox™ coverslips. These were then
and images assembled using Photoshop software. Note the reduction
, denoted by arrows on sessile cells.
Figure 2 CHD-FA kills and disrupts multi-species periodontal biofilms. Multi-species periodontal biofilms were grown on Thermanox™
coverslips within 24 well plates for a total of 5 days, with AS media changed every day. Upon biofilm development, cells were treated with 0.5%
(v/v) CHD-FA and 0.2% (v/v) CHX for 24 h before being washed with PBS. Reduction in metabolic activity was measured using the alamarBlue®
assay (A). All samples were assayed in triplicate, on three separate occasions. Data represents mean ± SD (***p < 0.0001). Biofilms were retained
after treatment with CHD-FA or CHX and DNA was extracted for quantification of each species using SYBR® GreenER™ based qPCR (B). Biofilms
were also analysed by SEM at either 2000x (C, E, G) and 5000x (D, F, H). These were processed and viewed on a JEOL JSM-6400 scanning
electron microscope and images assembled using Photoshop software. Untreated multispecies biofilms were first compared at low magnification
(C) to biofilms treated with 0.2% (v/v) CHX (E) and 0.5% (v/v) CHD-FA (G) for 24 h and it was shown that biofilm treatments caused
disaggregation. At higher magnification the biofilms treated with 0.5% (v/v) CHD-FA for 24 h resulted in a fibrous ECM, as denoted by arrows (H),
as compared to the control (D) and CHX (F).
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for CHD-FA, whereas for CHX this ranged from 2 to 64.
Overall, P. gingivalis was the most susceptible organism tothe antimicrobial therapies tested, particularly for plank-
tonic cells. In addition, all bacterial biofilms were equally
susceptible to CHD-FA with a SMIC of 0.5%.
Figure 3 CHD-FA is non-toxic against an oral epithelial cell line.
An orally relevant epithelial cell line (OKF6/TERT2) was grown to 90%
confluence in 24 well plates for toxicity studies. Cells were treated
with 0.5% (v/v) CHD-FA at pH 2.0 and 7.0 and with 0.2% CHX for
30 min. After treatment, cells were carefully washed with PBS and
cellular viability assessed using the alamarBlue® assay, with
absorbance read at 570 and 600 nm. All samples were assayed in
triplicate, on three independent occasions. Data represents mean ±
SD (***p <0.0001).
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physical cellular structure was assessed by SEM for repre-
sentative biofilms. CHD-FA treatment reduced the overall
quantity of S. mutans ECM (Figure 1B) and also caused
perturbation of the cell membrane, as demonstrated by
the punctured appearance of E. faecalis (Figure 1D).
CHD-FA is effective against a multi-species periodontal
biofilm
Given that biofilms of the oral cavity are polymicrobial in
nature, we developed a simple and reproducible multi-
species model representative of sub-gingival plaque to test
CHD-FA (Figure 2A). The antimicrobial activity of CHD-
FA at 1 x SMIC was shown to significantly reduce cell via-
bility to less than 10% (p < 0.0001), which was comparable
to the CHX, which also significantly reduced cell viability
to 8% (p < 0.0001). However, following treatment the num-
ber of each species within the biofilms were quantified
and showed no significant reduction in biomass after
CHD-FA or CHX treatment, compared to the untreated
control (Figure 2B).
SEM analysis of these biofilms was then performed to
evaluate any effect on the biofilm architecture (Figure 2C-
H). At low magnification (x2000) both CHX and CHD-FA
were shown to disrupt biofilm architecture (Figure 2E and
G) when compared to the untreated control (Figure 2C),
as shown by areas of sparse disaggregated biofilms. More-
over, at high magnification (x5000) CHD-FA also appeared
to alter the overall physical appearance of the biofilm
matrix with greater quantities of fibrous ECM observed as
denoted by the arrows (Figure 2H), compared to the con-
trol and CHX (Figure 2D and F).
CHD-FA alters the expression of pro-inflammatory mediators
CHD-FA toxicity was assessed using an orally relevant epi-
thelial cell line to determine whether there were any de-
trimental effects from the compounds tested prior to
immunomodulatory investigations. Both CHX and CHD-
FA, at its native pH of 2.0, were shown to be highly toxic
towards to epithelial cells, reducing viability to less than
10% after 30 min exposure (Figure 3). However, when
CHD-FA was buffered to a neutral pH of 7.0, no signifi-
cant decrease in cell viability was observed.
We next set out to determine whether or not CHD-FA
was able to induce a biological response from the epithelial
cells, principally by measuring changes in immune media-
tors. To evaluate this, a four-species biofilm model was de-
veloped, where no toxicity issues were observed when in
contact with the epithelial cell line at 4 h (data not shown).
Moreover, we have shown that CHD-FA treated cells do
not significantly alter the release of IL-8 after 4 h and 24 h
(data not shown). Initial gene expression studies using the
RT2 Profiler on epithelial cells pre-treated with CHD-FA
prior to biofilm challenge showed a general down-regulation of pro-inflammatory mediators (Figure 4A).
Significant down-regulated genes included IL-6 (8.5 fold
[p = 0.018]), IL-1β (7.05 fold [p = 0.012]), TNFα (5.22 fold
[p = 0.013]) and IL-8 (4.24 fold [p = 0.021]).
We next focussed on IL-8 expression, one of the sig-
nificantly affected genes and a key mediator of periodon-
tal inflammation. At the mRNA level, IL-8 was
significantly down-regulated in cells pre-treated with
CHD-FA after 4 h, when compared to the untreated con-
trol (p = 0.0383) (Figure 4B). No statistically significant dif-
ference was observed after 24 h stimulation (p = 0.1712).
In addition, at the protein level, IL-8 release was shown
to be significantly down-regulated when cells were
pre-treated with CHD-FA, after 4 h (p = 0.008) and 24 h
(p = 0.0037) biofilm stimulation (Figure 4C). CHD-FA
alone had no effect on oral epithelial cell IL-8 mRNA or
protein expression (data not shown).
Discussion
Oral microbial diseases are typically mediated by biofilms;
communities of microorganisms that co-aggregate as
sticky and tenacious structures and which characteristic-
ally have increased resistance to antimicrobials [25]. We
recently reported that mouthwashes, including CHX were
ineffective against a range of clinical MRSA strains [10],
suggesting that alternative antimicrobial agents ought to
be investigated. Indeed, recent studies in C. albicans have
shown that the use of naturally derived molecules are ef-
fective against both orally and systemically derived isolates
[14,15]. Here we report that CHD-FA, a naturally derived
Figure 4 CHD-FA modulates key inflammatory mediators
in vitro. An oral epithelial cell line (OKF6) was grown to 90%
confluence in 24 well plates for assessing the effect of CHD-FA on
the host immune response. Cells were pre-treated with 0.5% (v/v)
CHD-FA pH 7.0 for 30 min, washed with PBS and stimulated with
the multi-species periodontal biofilm for 4 and 24 h. Untreated
controls were also included. Samples were assayed in triplicate and
on three separate occasions. RNA was extracted from the 4 h cell
lysates, cDNA synthesised and used in the RT2 Profiler to analyse the
expression of a panel of pro-inflammatory mediators (A). Duplicate
samples from two independent experiments were used in the RT2
Profiler. Data is represented by mean + 95% CI, relative to untreated
control. Samples were also assayed for IL-8 gene expression using
SYBR® GreenER™ based qPCR (B). Expression of IL-8 is represented
relative to housekeeping gene; GAPDH. Retained supernatants were
also used to measure IL-8 protein release by ELISA (C). All samples
were assayed in triplicate, on three independent occasions. Data
represents mean ± SD (*p < 0.05, **p < 0.01).
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microbial activity, and also elicits immunomodulatory
activity.
We first undertook a comparative assessment of CHD-
FA and CHX against a range of important bacteria associ-
ated with oral biofilm infections. Both molecules were
shown to effectively inhibit and kill planktonic cells, and
both compounds were also effective against biofilms. Anti-
microbial activity against planktonic bacteria has been
reported previously for oxifulvic acid, a derivative of
CHD-FA, where inhibition was observed against a range
of important clinical pathogens, including Pseudomonas
aeruginosa, Staphylococcus aureus and Streptococcus
pyogenes [26]. Notably, only marginally higher concentra-
tions of CHD-FA were required to kill the biofilm as com-
pared to planktonic cells, whereas for CHX the fold
change was up to 64 times, a phenomenon also reported
for CHD-FA against C. albicans biofilms [15]. Moreover,
CHD-FA showed a rapid rate of kill for the periodontal
pathogens tested as polymicrobial biofilms, as after 30 min
treatment cellular viability was reduced by ≥90%, which
was also observed for studies of C. albicans [15]. It is
recognised that a potential limitation of this study is that
it was performed on biofilms produced from laboratory
strains of the periodontal organisms in vitro and it is con-
ceded that further investigation may be required to assess
the anti-microbial properties against the most virulent of
clinical strains and biofilms formed from ex vivo biofilms
or in vivo within experimental gingivitis models. Neverthe-
less, collectively, these data suggest that CHD-FA has po-
tent and broad-spectrum activity against microbial
biofilms. Furthermore, the SEM images indicate an action
against the bacterial cell membrane. Interestingly, the
biofilms appeared to be disaggregated and displayed a fi-
brous appearance, presumably as a consequence of cell
lysis and release of intracellular components of the bacter-
ial cells. Our previous studies on C. albicans biofilms do
Sherry et al. BMC Oral Health 2013, 13:47 Page 9 of 10
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biofilms was observed [15]. However, the filamentous na-
ture of C. albicans biofilms may explain why the com-
pound was unable to disaggregate these. Despite this
finding, there was no significant difference in the number
of each species when treated with antimicrobial therapy,
when compared to the untreated control. Though our
assay was unable to determine whether these were live or
dead.
Given that CHD-FA displayed an excellent antimicro-
bial profile, we wanted to ascertain whether it possesses
any other biological properties, as has also been demon-
strated for other naturals including tea tree oil [27]. It
has been reported that CHD-FA has no toxicity in rats
and humans, and it has been further suggested that it
elicits anti-inflammatory and wound healing promoting
properties [17,28]. Periodontitis is characterised by
chronic inflammation that leads to tissue and bone de-
struction [29], therefore controlling these processes is an
attractive option for clinical management. The use of
in vitro multi-species oral biofilms to study the inflam-
matory processes driven by complex biofilms have been
shown to be important [30], therefore we developed a
similar system to test CHD-FA and other bioactive mol-
ecules. Both CHX and CHD-FA in their native forms
were shown to be toxic, therefore, in order to demon-
strate subtle biological effects we buffered CHD-FA to
pH 7.0 in order to test our hypothesis that it was immu-
nomodulatory in vitro. Using an orally relevant epithelial
cell line stimulated with a polymicrobial biofilm we
demonstrated that at the transcript level cells treated
with CHD-FA showed a significant down-regulation of
pro-inflammatory molecules, including the chemokine
IL-8. Analysis of the IL-8 protein also showed a signifi-
cant reduction in its release from oral epithelial cells.
These data indicate that CHD-FA has bioactivity against
mammalian cells, as has been reported elsewhere
[17,28]. However, we accept these differences are only
observed when CHD-FA is adjusted to a neutral pH,
therefore, further studies are required to determine the
most suitable formulation of CHD-FA to potentially be
used clinically, which at present is formulated at pH 2.8.
At present, however, the precise mechanism of action re-
mains unknown, but we can only speculate that CHD-
FA interacts with membrane proteins resulting in
blocking signalling pathways, which leads to down-
regulation of pro-inflammatory mediators on stimulation
with biofilms. This is currently subject to further investi-
gation by our group.
Conclusions
This study has demonstrated that the naturally derived
compound CHD-FA exhibits broad-spectrum antimicro-
bial activity against orally relevant biofilm organisms.Although a four species mixed biofilm model was used
in this study, we are aware that antimicrobial activity
against this model does not fully represent all mixed
biofilms that are found within the oral cavity, but only a
few of species relevant in periodontal disease. It further
shows that CHD-FA has the capacity to modulate the
immune response and down-regulate the biofilm in-
duced expression of pro-inflammatory mediators in oral
keratinocytes. However, a further limitation of this study
was only a selected number of inflammatory mediators
were investigated, thus precluding other host factors for
consideration, which may influence the inflammatory re-
sponse even further. Collectively, these properties make
CHD-FA an attractive option for the development of a
mouthwash to treat microbial oral disease; although fur-
ther studies in vitro and in vivo are first required to further
define the mode of action of this unique compound.
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